COVID-19 vaccines approved by WHO. EUA-Emergency use authorization
Schematic representation of the proposed mechanism of action of
PTX3 deficiency is associated with reduced inflammation and innate
Overview of failed and related ongoing phase II and III trials in
composition (mol%) of the bioactive polysaccharides fractions
Mechanisms mediating immunomodulation. MSCs and their derived
Summary of the molecular and cellular effects observed after
Global spread of COVID-19, showing the number of confirmed cases
PRISMA guidelines for article identification and selection
The MSC treatment doses, route of administration, treatment
Nicola VANNINI, Group Leader, PhD
First step trial selection by searching in the International